Improving Treatment Decisions for Sepsis Patients by Reinforcement Learning by Lyu, Ruishen
   
Title Page  
Improving Treatment Decisions for Sepsis Patients by Reinforcement Learning 
 
 
 
 
 
 
 
 
 
 
by 
 
Ruishen Lyu 
 
BS in Preventive Medicine, China Medical University, China, 2018 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of the 
 
Graduate School of Public Health in partial fulfillment 
  
of the requirements for the degree of 
 
Master of Science 
 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
2020
 ii 
Committee Page 
UNIVERSITY OF PITTSBURGH 
 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Ruishen Lyu 
 
 
It was defended on 
 
April 17, 2020 
 
and approved by 
 
Thesis Advisor: Lu Tang, PhD, Assistant Professor, Department of Biostatistics  
Graduate School of Public Health, University of Pittsburgh 
 
Thesis Co-Advisor: Chung-Chou H. Chang, PhD, Professor, Departments of Medicine and 
Biostatistics  
School of Medicine and Graduate School of Public Health, University of Pittsburgh 
 
Committee Members: Florian Mayr, MD, MPH, Assistant Professor, Department of Critical 
Care Medicine  
School of Medicine, University of Pittsburgh 
 
  
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © by Ruishen Lyu 
 
2020 
 
 
 
 
 iv 
Abstract 
Lu Tang, PhD 
 
Chung-Chou H. Chang, PhD 
 
Improving Treatment Decisions for Sepsis Patients by Reinforcement Learning 
 
Ruishen Lyu, MS 
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Abstract 
 
 
Sepsis is defined as a dysregulated immune response to infection leading to acute life-
threatening organ dysfunction. Patients with sepsis have 25.8% intensive care unit (ICU) mortality, 
which was significantly higher than in the general ICU population. Making optimal medication 
decisions becomes an emergent and important task. The purpose of this study is to develop a data-
driven decision-making tool that can dynamically suggest optimal treatments for each individual 
ICU patient with sepsis, and help clinicians make better treatment decisions to improve patients’ 
long-term survival outcomes. 
Model-free Q-learning was applied to data extracted from the eICU Research Institute 
(eRI) database. We selected 3,800 patients admitted to ICUs with septic shock and summarized 
their first 7 days of lab results and vitals into 18,014 daily records. To identify best treatment 
decisions of vasopressor use, we first clustered patients’ demographics and daily medical 
conditions into 100 distinct states. We then mapped ICU survival to time-dependent rewards and 
estimated the Q-values for each action taken at each state using temporal-difference learning. 
Finally, we obtained the optimal policy that maximizes the action-value function by policy 
iteration. An off-policy evaluation method was implemented to evaluate the performance of 
several treatment policies. 
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The result showed that the Q-learning policy has significantly higher long-term average 
reward than the clinician policy or the random policy, meaning that patients who received 
treatments matching those suggested by the Q-learning policy had better survival outlook than 
those who did not.    
In conclusion, we showcased that the prospect of long-term survival may be improved 
through using modern reinforcement learning methods that optimizes the rewards against the 
dynamics of the environment. 
Public Health Significance: We developed a data-driven automatic reinforcement 
learning tool and applied it to an electronic health database of sepsis patients.  The result showed 
that medical decisions that matched our Q-leaning policy led to better survival outlook; this 
suggests that machine learning can be used to help clinicians decide the most effective treatments 
and reduce the burden on medical and economical resources. 
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1.0 Introduction 
Sepsis is defined as a dysregulated immune response to infection leading to life-threatening 
acute organ dysfunction (Seymour et al., 2019). It is also a common global health issue associated 
with a high mortality rate and a low quality of life after survival. Based on a study from the 
Intensive Care Over Nations (Vincent et al., 2014), 29.5% of patients had sepsis on admission to 
the intensive care unit (ICU). The study also noted that one out of four patients with sepsis died in 
the ICU and one out of three could not survive until hospital discharge. With increased sepsis 
severity, rising costs and worsening outcomes show a great burden in economic and epidemic 
perspectives (Paoli, Reynolds, Sinha, Gitlin, & Crouser, 2018).  
Most of the patients (72%) with sepsis before admission had comorbidities such as 
respiratory tract, urinary tract or gastrointestinal infections (Novosad et al., 2016). There are 
different severities of sepsis ranging from systemic inflammatory response syndrome (SIRS), 
sepsis, severe sepsis, to septic shock. The 28-day mortality increases from approximately 10% 
with SIRS to 40%-60% with septic shock (Brun-Buisson, 2000). There is a high mortality rate 
during the first 48 hours after admission and a high incidence of multiple organ failures at 
diagnosis, which suggests there are delays in the initial diagnosis of sepsis and starting antibiotic 
therapy (Blanco et al., 2008).  
Making optimal medication decisions for patients with different medical conditions and 
different characteristics is a challenge to date. The severity of diseases and heterogeneity of 
medical conditions of patients in the ICU requires more advanced and precise medical decisions 
(Ng et al., 2018). Also, it is important for clinicians to keep in mind the long-term goals of curing 
sepsis, rather than providing treatments that only offer immediate relief of the patients’ symptoms. 
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The progression of the disease can develop rapidly for patients while in the ICU, so it is important 
for clinicians to make an optimal decision in a short period of time. Therefore, quick and 
personalized treatments with the best long-term outcomes are in high demand. 
Reinforcement learning is a class of machine learning methods that can be used to help 
sequential decision making toward predefined long-term terminal goals (Burkov, 2019). Machine 
learning methods usually involve training an agent to learn and react to an environment through 
trial and error. Since an action taken by the agent could potentially have different effects on 
individuals over time, we designed the agent to be adaptive and immediately responsive to change 
during such interactions. By adjusting rewards for different actions in different conditions, the 
learning agent can learn and develop rules for achieving the long-term goal. 
Q-learning is a reinforcement learning method that can solve sequential decision-making 
problems by estimating the Q-values, which represent the overall quality, or more rigorously 
defined as the expected cumulative rewards, of different actions made in each of the different 
states. There are model-based Q-learning methods, such as Markov Decision Process (MDP), and 
non-model-based Q-learning methods, such as Temporal-Difference (TD) learning and deep Q-
learning. The research conducted by Komorowski et al., (2018) adopted MDP to establish an 
artificial intelligence agent to suggest decisions to sepsis patients. In order to solve the sequential 
decision-making problem, the MDP decomposes the learning procedure into estimating the state 
transition, and the reward value is dependent only on the current state and applied action.  
MDP is best applicable to deterministic environments where transition and reward are 
known in advance. However, in most real world settings, state transition and reward value are 
probabilistic and cannot be estimated precisely based on data collected from non-controlled 
settings, which is especially the case in ICUs (Pardo, Tavakoli, Levdik, & Kormushev, 2017). The 
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model-free Q-learning method can be used to train an agent without needing to estimate the reward 
and state transition functions. Examples of model-free methods include the Monte Carlo method 
and the TD method. Rather than being limited in the observed state-action pairs, they can explore 
all possibilities of state-action pairs and estimate the long-term reward that will be received by 
choosing an action in certain state. Model-free Q-learning can develop a ‘critic’ by measuring the 
‘quality’ of different state-action pairs and identify the optimal action-selection policy that 
maximizes the long-term reward (Watkins, 1989). 
By using reinforcement methods, clinicians can address issues resulted from the 
heterogeneity of patients and the delayed indications of the efficacy of treatments. Reinforcement 
learning can be designed to seek higher long-term returns over the immediate rewards so that the 
resulting policy will maximize the final outcome of patients. Reinforcement learning methods have 
been applied to solving a number of medical problems and provided the optimal suggestions for 
clinicians and patients (Komorowski et al., 2018; Saria, 2018; Srinivasa Rao & Diamond, 2020). 
The purpose of this study is to develop a data-driven decision-making tool that can 
dynamically suggest optimal treatments for each ICU patient with sepsis, and help clinicians make 
better treatment decisions to improve patients’ long-term survival outcomes. Section 2 (Method) 
introduces the dataset and the model-free Q-learning method applied in the study. Section 3 
(Result) presents the results from the data analysis, and Section 4 (Discussion) concludes the study 
based on the results.  
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2.0 Method 
2.1 Data 
Our data was extracted from the publicly available eICU Research Institute Database (eRI) 
(Pollard et al., 2018), which is a multi-center data set comprised of de-identified electronic health 
data with over 200,000 admissions to ICUs across the United States from 2014-2015. The database 
includes vital sign measurements, care plan documentation, severity of illness measures, diagnosis 
information, and treatment information. We selected 3,800 patients with septic shock based on the 
ICD-9 diagnosis code (785.52) within the first 24 hours of admission. For each patient, we 
summarize their daily information over the first 7 days since hospital admission, which resulted in 
a total of 18,014 daily records. The in-hospital survival status was also extracted. The final analytic 
data set includes 25 variables of patients’ demographics, Elixhauser premorbid status, vital signs, 
and laboratory values. The treatments received in each daily record of the individual patients were 
also included in the dataset. The observations with age less than 18 were excluded. The 
observations with no documentation in the discharge outcome or incomplete daily records were 
also excluded. After applying exclusion criteria, we used 17,825 records of 3,726 patients in the 
later model building. 
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2.2 Data Preparation 
We examined the above-mentioned 25 variables including the distribution characteristics, 
missing percentage, data range, and outliers. The temperature unit was unified to Fahrenheit. We 
used multivariate imputation by chained equations (MICE) with 5 multiple imputations and 5,000 
maximum iterations to impute the missing values in the dataset (Azur, Stuart, Frangakis, & Leaf, 
2011). For the purpose of clustering, all variables were converted to normality if necessary. 
Variables related to erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and troponin 
concentrations were excluded because of high percentage of missingness or unadjusted 
abnormality. 
Treatment of sepsis patients with vasopressors is our major interest in the study. There are 
different types of vasopressors. Based on the administration of vasopressors, we categorized 
treatments into first-line vasopressors (norepinephrine and epinephrine), second-line vasopressors 
(phenylephrine and vasopressin), and others (Stratton, Berlin, & Arbo, 2017). Due to unbalanced 
distributions of different treatments and the clinical significance, we identified four possible 
treatment actions related to the use of vasopressors, including: 1) first-line only (NE): 
norepinephrine or epinephrine, 2) second-line only (PVO):  phenylephrine, vasopressin, dopamine 
or others, 3) first-line and second-line (NEPVO) norepinephrine or epinephrine with 
phenylephrine, vasopressin or others, and 4) no treatment used (None). 
Unsupervised clustering was used to divide patients’ clinical conditions into a finite set of 
more homogeneous groups. Based on the clustering results, we assigned each patient at each day 
to a cluster so that the patient’s data point has the shortest distance to the center of that cluster as 
compared with the distance to the center of any other clusters. The 𝐾-means clustering method 
was used with 1,000 random starts, maximum iteration of 5,000 times, and the predefined number 
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of clusters 𝐾 = 100. We further ranked the 100 clusters based on their in-hospital mortality rates 
(Table 1), which is the proportion of the number of patients who died over the total number of 
patients in each cluster. The lower ranks represent higher mortality rates and higher ranks represent 
lower rates. 
Table 1 Mortality rates for states 
State 
Mortality 
Rate 
Sample 
size 
Mortality 
ranking  State 
Mortality 
Rate 
Sample 
Size 
Mortality 
Ranking 
15 77.8% 63 1  98 18.7% 75 51 
85 62.5% 80 2  31 18.1% 144 52 
45 50.9% 112 3  6 17.7% 164 53 
39 50.0% 42 4  62 17.6% 102 54 
21 43.7% 135 5  68 16.8% 173 55 
4 41.3% 104 6  67 16.1% 155 56 
80 41.0% 78 7  16 16.1% 211 57 
86 40.6% 96 8  75 16.1% 205 58 
19 36.9% 122 9  10 15.6% 192 59 
28 35.5% 172 10  27 15.5% 161 60 
35 34.4% 131 11  63 15.3% 131 61 
14 33.3% 150 12  88 14.8% 81 62 
24 33.3% 78 13  87 14.8% 169 63 
72 33.3% 30 14  43 14.7% 170 64 
74 33.3% 141 15  66 14.4% 153 65 
60 33.1% 133 16  52 13.9% 202 66 
100 32.9% 82 17  44 13.7% 139 67 
57 32.7% 150 18  2 12.9% 178 68 
5 31.4% 102 19  11 12.8% 109 69 
92 30.9% 175 20  23 12.7% 142 70 
20 30.0% 150 21  91 12.7% 150 71 
97 29.5% 105 22  81 12.3% 171 72 
71 29.2% 120 23  7 12.3% 163 73 
56 28.5% 151 24  83 12.1% 190 74 
40 28.2% 85 25  41 11.7% 188 75 
55 27.9% 61 26  82 11.6% 215 76 
95 27.6% 127 27  69 11.6% 121 77 
33 26.7% 172 28  18 11.3% 194 78 
49 26.4% 159 29  12 10.8% 120 79 
22 26.3% 156 30  64 10.4% 249 80 
58 25.6% 117 31  65 10.2% 118 81 
76 24.2% 157 32  8 10.1% 237 82 
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2.3 Basics of Reinforcement Learning 
Reinforcement learning has been used to solve the sequential decision-making problem in 
order to maximize the long-term goal. In our study, we use the reinforcement technique to 
determine the optimum daily vasopressor use for each patient that will maximize the patient’s in-
hospital survival. There are three key entities in the setting: state, reward, and action, that enable 
the agent to interact with the environment and develop a policy. We specify these three entities 
and other key elements below. 
Time: The study period was divided into equally spaced discrete intervals since hospital 
admission. Each patient has up to 7 daily records. 
State: We categorized patients’ medical conditions into 100 unique states which were 
determined based on the K-mean clustering method by using the 25 demographics, Elixhauser 
50 24.1% 162 33  99 9.9% 162 83 
42 23.4% 124 34  13 8.9% 224 84 
34 23.4% 154 35  84 8.8% 160 85 
37 23.3% 146 36  73 8.2% 183 86 
51 23.1% 143 37  25 7.5% 201 87 
53 22.7% 141 38  96 7.4% 149 88 
48 22.5% 173 39  36 7.3% 123 89 
61 22.1% 145 40  29 7.3% 193 90 
32 22.0% 182 41  54 6.7% 165 91 
38 22.0% 164 42  46 6.6% 136 92 
30 21.7% 161 43  78 6.5% 169 93 
93 21.6% 148 44  70 4.4% 180 94 
9 21.0% 214 45  79 4.4% 181 95 
17 20.7% 111 46  94 3.6% 137 96 
77 20.0% 130 47  90 3.4% 148 97 
47 19.3% 114 48  3 3.0% 164 98 
1 19.0% 163 49  26 3.0% 101 99 
89 19.0% 195 50  59 0.7% 146 100 
Table 1 Continued 
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premorbid status, vital signs, and laboratory values for all 17,825 records of 3,726 patients. From 
time 𝑡 to time 𝑡 + 1, a patient may transition from one state to another. Notation 𝑆𝑡  and 𝑆𝑡+1 
represent a patient’s current state (at time 𝑡) and the next state (at time 𝑡 + 1). Table 2 shows the 
reinforcement learning input dataset for patient 𝑖, 𝑖 = 1, …, 3726. Each patient has at most 6 
transitions because the value of the ‘next state’ for the last time point is unknown. In Table 2, the 
example patient who survived the first 7 days has 6 records in the end. 
Reward: At each time 𝑡, we assigned reward 𝑅𝑡 to be 0 for all patients except for the last 
record. For the last record, we assigned a reward of 100 to those patients who survived in hospital 
and -100 to those patients who died in hospital (see Table 2). The rationale for giving zero rewards 
before the final transition is to rule out the possibility of an agent learning some treatment policy 
that only provides short-term conditional relief to patients but fails to gain long-term improvement 
in survival. 
Action: The action at each time 𝑡 for each patient, 𝐴𝑡 refers to the vasopressor the patient 
received at that day. Based on the vasopressor administration guidelines (Stratton et al., 2017), we 
categorized different vasopressors into the following 4 combinations of treatments: first-line 
vasopressors only (NE: norepinephrine or epinephrine), second-line vasopressors only (PVO: 
phenylephrine, vasopressin, or others), combination of the first-line and the second-line 
vasopressors (NEPVO), and no vasopressor (None). 
 
Table 2 Example transition of a patient who survived the first 7 days 
Patient ID Time State Next State Reward Action 
00001 1 60 45 0 NE 
00001 2 45 70 0 NE 
00001 3 70 16 0 PVO 
00001 4 16 25 0 PVO 
00001 5 25 16 0 NE 
00001 6 16 9 100 None 
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Generally speaking, state, reward, and action can be defined as either continuous or 
discrete. We applied reinforcement learning method with discretized state and time defined by 
homogeneous patient conditions (aka clusters) and daily time windows, but we will also discuss 
the possibility of extending to the continuous patient states. 
2.4 Q-learning 
Agent and Environment: The agent is one who takes actions based on the rewards in 
different states. The environment is what the learning agent interacts with and learns from. 
Different states, rewards, and actions shape the environment that limit the learning agent (Sutton 
& Barto, 2018). As shown in Figure 1, the interactions between the learning agent and the 
environment is continuous as if in a sequential situation. The learning agent selects actions and the 
environment responds with corresponding states and rewards. The intrinsic characteristics of 
reinforcement learning drives the agent toward yielding the most optimal policy that maximizes 
the cumulative rewards it receives in the long run. 
 
Figure 1 Interaction between Agent and Environment 
(Sutton & Barto, 2018) 
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Policy: The policy is the set of rules that the learning agent develops to select an action in 
a state. The optimal policy is the rule that is recommended to follow for achieving the most optimal 
long-term reward. In this study, we will compare three different policies: clinician policy, random 
policy, and the optimal policy where clinician policy is based on clinicians’ selection of 
vasopressors for each patient at each day; random policy is based on the random treatment 
selection from NE, PVO, NEPVO, and None with equal chance; and optimal policy was the best 
treatment selection based on the reinforcement Q-learning procedure. 
Policy Value: Given a policy, the policy value represents the expected future reward 
collected at each state, or for each state-action pair. In our study, the value for each state is a vector 
of dimension 100; and the value for state-action pair is a matrix of 100 by 4. This value function 
also suggests possible improvement to the current policy, leading to an update of the current policy. 
In Q-learning, the mapping from states, or state-action pairs, to values are commonly known as 
the Q-value function, hence the name Q-learning for the algorithm to estimate the Q-value 
function. In this study, the policy value is the value of the policy that was estimated to be the 
survival after receiving vasopressors from the Q-learning policy. 
Markov property assumes that all aspects of the past agent-environment interaction that 
make a difference for the future are included in the current states (Sutton & Barto, 2018). In other 
words, how a patient may respond to a treatment under certain conditions (aka state) is 
probabilistically fixed. By breaking the continuing interactions into different episodes with 
{𝑠, 𝑎, 𝑟, 𝑠′}, the sequential problem was decomposed into a memoryless series. The next state 𝑠′ 
and the reward value 𝑟 depend only on the current state 𝑠 and the applied action 𝑎. In the dataset, 
we defined each patient’s information at each time period as {𝑠, 𝑎, 𝑟, 𝑠′}, and the collection of 
information across all time periods of a patient as an episode. An episode summarizes the trajectory 
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of a patient’s hospital stay. It describes the actions in states and corresponding reward from day 1 
up to day 7 leading to the survival outcome of every patient. Q-learning method was used to solve 
the sequential decision-making problems by estimating the Q-values, the expected cumulative 
rewards, associated with different actions made in different states. 
There are model-based Q-learning methods, such as Markov Decision Process (MDP), and 
non-model-based Q-learning methods, such as temporal-difference learning (TD-learning). Both 
MDP and TD learning methods assume that state, reward, and action can only take a discrete and 
a finite set of values. Time horizon can be finite or infinite depending on real applications. MDP 
is a specific formalism to describe an environment’s dynamics and a decision problem to solve 
within. It is the benchmark reinforcement learning method applicable in many classical settings, 
such as solving a maze. MDP is a model-based learning method that requires knowing the 
dynamics between states, actions and corresponding rewards. However, when such environment 
dynamics are not well defined, as in the case of treatment-response dynamics, MDP requires fully 
observable state-action pairs {𝑠, 𝑎} to estimate the model for the environment. This is not suitable 
in real clinical scenarios because there are circumstances when certain types of treatments are 
strictly prohibited for certain types of patients, thus no observed data on the rewards. Therefore, 
such a complicated setting with different combinations of treatments and states is not enough 
information for the MDP. Even with a very large dataset, the observable state-action pairs {𝑠, 𝑎} 
may still be insufficient to describe all possible combinations of the many treatment choices and 
heterogeneous patient states. On the contrary, TD-learning was used to bypass the need of a model. 
It directly approximates the Q-values using weighted average of past experiences (Sutton & Barto, 
2018): 
𝑞𝑘(𝑠, 𝑎) = (1 − 𝛼𝑘)𝑞𝑘−1(𝑠, 𝑎) + 𝛼𝑘(𝑟 + 𝛾𝑞𝑘−1(𝑠
′, 𝑎′)) 
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TD-learning approximates the Q-values by using the past value of itself. The Q-values of 
the actions in different states that the learning agent made are computed. The higher Q-values 
mean the patients will receive higher rewards if they take certain actions in different states. By 
exploring all possibilities of state-action pairs, TD-learning can estimate the long-term rewards 
that patients will receive by choosing an action in a certain state. The resulting state-action value 
function 𝑄𝜋(𝑠, 𝑎) is a mapping of the expected sum of rewards starting from a certain state 𝑠, 
taking the action 𝑎, and thereafter following policy π (Bennett & Hauser, 2013; Sutton & Barto, 
2018). The estimation was conducted based on the transition data consisting of four elements, 
including ‘State’, ‘Action’, ’Reward’, and ‘Next State’, {𝑠, 𝑎, 𝑟, 𝑠′}, for different daily records of 
3,726 patients, 14,099 records in total. 
 
Figure 2 Flowchart of policy building 
By observing the actual policy followed by clinicians, the learning agent learns from the 
state-action pair episodes {𝑠, 𝑎} from the clinician policy to develop the iteration and generate the 
most optimal policy 𝜋∗. The policy iteration involved initialization, policy evaluation and policy 
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improvement. The policy iteration starts with a random policy and compares different policies 
based on the action value function 𝑄𝜋(𝑠, 𝑎), and finds another new policy based on the previous 
action value function. In the end, the policies converge to the most optimal policy (Sutton & Barto, 
2018).  
𝜋∗(𝑠) ← 𝑎𝑟𝑔 max
𝑎
𝑄𝜋
∗
(𝑠, 𝑎), ∀𝑠 
The policy iteration algorithm requires pre-specification of three controlling parameters, 
learning rate α, discount factor γ, and the probability of random actions ε. The learning rate can 
control how quickly the learning agent adapts to the random changes imposed by the environment. 
The discount factor 𝛾 ∈ [0, 1) quantifies how much importance is given to future rewards. In the 
study, we set gamma to be 0.99, which is high enough to encourage the learning agent to consider 
future rewards rather than immediate rewards. The 𝜀 -greedy method was used for actions 
exploration in the study with 𝜀 as 0.1. The 𝜀  means that the learning agent would exploit the 
treatments to obtain maximum immediate reward with a 90% probability, and there is a 10% 
probability that the learning agent would explore other treatments in order to maximize the long-
term reward. The 𝜀 will decay during the iteration, because after exploring the other possible 
actions, it will exploit the known actions more in the same state (Sutton & Barto, 2018). 
We used the R package ReinforcementLearning with the experience replay algorithm, 
which creates a buffer that stores different ‘experience’ when the learning agent interacts with the 
environment. The experiences are different episodes with {𝑠, 𝑎, 𝑟, 𝑠′},  from different policies. The 
experience buffer allows the learning agent to randomly select a batch of data from the buffer, 
which not only can reduce time of policy iteration and increase the data efficiency, but also 
improve the training performance with lower variance based on more diverse batch data (Mnih et 
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al., 2015). The iterations were set as 5,000 to make the Q-value converge to the maximum value 
for each action in the study. 
2.5 Model Evaluation 
Off-policy evaluation was conducted to measure the performance of the Q-learning policy 
based on the patient trajectories observed under the clinician policy. The value of a policy is 
defined in terms of the likelihood of survival under the proposed policy. Since difference policies 
could lead to different distributions of observable patient populations, we can view the data 
generated from two different policies as two population samples. In order to quantify the rewards 
a patient receives hypothetically if they follow the proposed policy, the rewards were reweighted 
by importance sampling weights. This is a common technique used in causal inference for 
generalizing results from one population to another. The hypothetical sample through reweighing 
mimics the patient population arising from the proposed Q-learning policy (Jiang & Li, 2016; 
Thomas, Theocharous, & Ghavamzadeh, 2015). In other words, the observed rewards from the 
clinician policy will be reweighted to approximate the rewards from the proposed policy of 
interest. Using this technique, we evaluate both the Q-learning policy and the random treatment 
policy. 
To calculate the importance sampling weights for a proposed policy, first, the per-step 
importance ratio was calculated: 𝜌𝑡
(𝑖)
= 𝜋1(𝑎𝑡
(𝑖)|𝑠𝑡
(𝑖))/𝜋0(𝑎𝑡
(𝑖)|𝑠𝑡
(𝑖)
), where 𝜋1(𝑎𝑡 |𝑠𝑡) denotes the 
probability of choosing treatment 𝑎𝑡 at state 𝑠𝑡 based on the proposed policy; and the 𝜋0(𝑎𝑡| 𝑠𝑡) 
denotes the probability of choosing treatment 𝑎𝑡 at state 𝑠𝑡 based on the existing clinician policy. 
Although policy probabilities are insensitive to time, they are trajectory specific. To evaluate the 
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Q-learning policy, 𝜋1 will be the derived policy from the Q-values of our learning algorithm; to 
evaluate the random policy, 𝜋1 will be a policy with the same probability, 0.25, for choosing every 
treatment in every state. For a given patient 𝑖, a cumulative per-step importance ratio up until time 
𝑡  was calculated by multiplying the ratios of daily records, 𝜌1:𝑡
(𝑖)
= ∏ 𝜌
𝑡′
(𝑖)𝑡
𝑡′=1 . A normalizing 
quantity 𝑤𝑡 for cumulative ratio at time horizon 𝑡 was estimated by averaging 𝜌1:𝑡 from subjects 
with trajectories of at least length 𝑡. By definition, 𝑤𝑡 = ∑ 𝜌1:𝑡
(𝑖)/|𝐷𝑡|
|𝐷𝑡|
𝑖=1 , where |𝐷𝑡| is the number 
of subjects with trajectories of at least length 𝑡. In our setting, 𝑤𝑡, 𝑡 ∈ {1, … , 6}, can only take 6 
unique values. The weighted reward of each trajectory based on weights of importance sampling 
(WIS) for patient 𝑖 was estimated by 
𝑉𝑊𝐼𝑆
(𝑖)
=
𝜌
1:𝐻(𝑖)
(𝑖)
𝑊
𝐻(𝑖)
(∑ 𝛾𝑡−1𝑟𝑡
(𝑖)𝐻(𝑖)
𝑡=1 ), 
where 𝐻(𝑖) is the number of records the patient had. Patients with different histories of visits have 
different weights of importance sampling. As previously defined, 𝛾 is the discount factor with 
value 0.99, 𝑟𝑡  is the reward the patient received at each time point. The average reward of all 
patients was estimated by 
𝑊𝐼𝑆 =
1
𝑛
∑ 𝑉𝑊𝐼𝑆
(𝑖)𝑛
𝑖=1  . 
We then evaluated the performance of the clinician, random, and reinforcement learning 
policies by comparing their average trajectory-wise rewards. 
By using bootstrapping with the off-policy evaluation performed 50 times, the true 
distribution of the policy value was estimated (Hanna, Stone, & Niekum, 2017). The values of the 
Q-learning policy, the clinician policy, and the random policy were constructed and compared by 
using the one-way analysis of variance at the significance level of 5%. The post-hoc test with 
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Bonferroni correction was performed to compare the difference between each pair of the policy 
values.  
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3.0 Results 
Below we show results on four domains. The first is a descriptive summary that shows the 
original variables we included in the study from the dataset and the variables after standardization 
and imputations. Next, we present the means of variables in different survival ranks to demonstrate 
the state identification. Third, we present the differences between the clinician policy and the Q-
learning policy. Last, we present a quantitative evaluation and comparison of Q-learning policy, 
clinician policy, and random policy. Our model-free Q-learning approach produces the most 
optimal policy that allows patients to receive the maximum long-term rewards. 
3.1 Descriptive Statistics 
Table 3 shows the summary statistics of the 25 variables of patients; demographics, 
Elixhauser premorbid status, vital signs, and laboratory values from the original dataset. The 
frequency and percentage of missing data for each of the variables are presented at the last column 
of each table.  
In preparation for subsequent clustering analysis, we first excluded erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), and troponin concentrations because of high 
percentage of missingness. We then standardized the rest of the 22 variables by subtracting its 
mean and then dividing by its standard deviation (SD). The missing data of the standardized 
variables were then imputed using the MICE method with 5 replications. The descriptions of the 
final imputed data are summarized in Table 5. 
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An overall description of vasopressor use was summarized in Table 3. The no treatment 
(None) option was used the most (51.3%), while the first-line vasopressor only (NE) was the least 
prescribed treatment option by clinicians. The description of treatment frequency over 7 days is 
shown in Table 4. The frequency of first-line vasopressor (NE) decreases from day 1 to day 7, 
while the frequency of no vasopressor treatment (None) increases from day 1 to day 7. Among the 
3,726 patients included in this study, the in-hospital mortality rate was 22.8%. 
 
Table 3 Descriptive statistics for the baseline variables 
  
Missing (%) 
Mean 
or 
Median 
(SD) 
or 
(IQR)   Min Max 
Normally distributed continuous variables, mean (SD) 
Age 860 4.80% 64.9 15.2  18 89 
Bicarbonate 2314 13.00% 24.1 5  3 47 
Chloride 757 4.20% 107.2 6.9  74 155 
RR 16807 94.30% 20.5 7.2  0 50 
Sodium 722 4.10% 140.4 5.6  116 179 
Temperature 15742 88.30% 37.1 0.6  32.2 41.2 
Heart rate 4221 23.70% 112.4 22.3  43 300 
Systolic BP 13233 74.20% 156.6 36.4  -6 351 
Nonnormally distributed continuous variables, median (IQR) 
Albumin 8509 47.70% 2.3 2 2.8 0.6 6 
Bands 15512 87.00% 8 3 17 0 92.5 
ALT 9665 54.20% 33 18 84 3 10940 
AST 9613 53.90% 41 22 100 3 31664 
BUN 772 4.30% 28 16 45 1 261 
Creatinine 725 4.10% 1.2 0.8 2.2 0.1 15.7 
CRP* 17576 98.60% 17.6 8.4 479 0.2 4723 
ESR* 17584 98.60% 49 28 72 1 139 
Glucose 803 4.50% 128 102 167 6 1791 
Hgb 1236 6.90% 9.6 8.6 10.9 4.4 19.5 
Lactate 13218 74.20% 2.1 1.3 4 0.2 36.7 
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O2 sat 12476 70.00% 97 95 99 12 101 
PaCO2 11826 66.30% 39.3 33.3 47 11.6 161.6 
Platelets 1402 7.90% 163 100 239 2 1102 
INR 12215 68.50% 1.5 1.3 2.2 0.9 23.6 
Troponin* 17578 98.60% 0.1 0.1 0.6 0 26.9 
WBC 1368 7.70% 12 8.2 17.6 0 402.8 
Categorical variables, n(%) 
      n (%)       
Female     8447 0.474    
Treatment            
NE     1113 0.062    
PVO     3185 0.179    
NEPVO     4377 0.246    
None     9150 0.513    
Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase, BUN: blood 
urea nitrogen, Hgb: hemoglobin, O2 sat: oxygen saturation, PaCO2: partial pressure of carbon 
dioxide, INR: prothrombin time international normalized ratio, RR: respiratory rate, WBC: 
white blood cell count, BP: blood pressure. 
*Variables CRP, ESR, and Troponin were excluded. 
 
 
Table 4 Treatment frequency over 7 days 
 N (Probability) 
 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 
NE 530 
(14.3%) 
296 
(8.9%) 
134 
(4.7%) 
68 
(2.7%) 
45 
(2.1%) 
20 
(1.1%) 
20 
(1.3%) 
PVO 551 
(14.9%) 
567 
(17.1%) 
564 
(19.6%) 
463 
(18.7%) 
403 
(18.9%) 
353 
(19.5%) 
284 
(18.8%) 
NEPVO 1472 
(39.8%) 
1118 
(33.7%) 
693 
(24.1%) 
432 
(17.4%) 
296 
(13.9%) 
211 
(11.7%) 
155 
(10.3%) 
None 1143 
(30.9%) 
1339 
(40.3%) 
1488 
(51.7%) 
1515 
(61.1%) 
1393 
(65.2%) 
1224 
(67.7%) 
1048 
(69.5%) 
Total 3696 3320 2879 2478  2137 1808 1507 
 
 
 
 
Table 3 Continued 
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Table 5 Descriptive summary of variables after standardization and imputation 
  Mean (SD) Median (IQR)   Min. Max. 
Age 0.01 1.00 0.14 -0.59 0.79 -3.09 1.58 
Albumin 0.00 1.00 0.00 -0.54 0.76 -5.16 3.68 
ALT -0.05 0.96 -0.26 -0.74 0.39 -2.04 4.12 
AST -0.05 0.96 -0.25 -0.73 0.36 -2.19 4.77 
Bands -0.07 1.00 -0.03 -0.85 0.68 -2.30 2.47 
Bicarbonate -0.01 1.00 -0.02 -0.61 0.58 -4.18 4.54 
BUN 0.00 1.00 0.10 -0.63 0.72 -4.28 3.03 
Chloride 0.00 1.00 -0.03 -0.61 0.69 -4.79 6.90 
Creatinine 0.00 1.00 -0.14 -0.73 0.70 -3.51 3.33 
Glucose 0.10 1.10 -0.51 -0.52 0.38 -0.53 4.61 
Hgb 0.13 1.04 0.18 -0.74 0.81 -1.63 2.74 
Lactate 0.00 1.00 -0.11 -0.71 0.59 -8.20 6.86 
O2 sat 0.00 1.00 -0.07 -0.72 0.67 -4.65 4.08 
PaCO2 -0.25 0.91 -0.33 -0.93 0.24 -2.99 3.31 
Platelets 0.05 1.01 0.01 -0.84 0.59 -2.66 4.79 
INR 0.03 0.99 0.00 -0.59 0.57 -4.37 4.93 
RR 0.00 1.00 0.00 -0.68 0.66 -2.79 5.01 
Sodium -0.07 0.96 -0.34 -0.83 0.41 -1.46 5.75 
Temperature -0.08 1.02 -0.34 -0.76 0.49 -2.83 4.08 
WBC 0.00 1.00 -0.06 -0.60 0.64 -4.31 6.84 
Heart rate -0.01 0.97 -0.12 -0.12 -0.12 -8.09 6.89 
Systolic BP -0.09 0.53 -0.29 -0.32 -0.18 -0.34 12.14 
Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase, 
BUN: blood urea nitrogen, Hgb: hemoglobin, O2 sat: oxygen saturation, PaCO2: 
partial pressure of carbon dioxide, INR: prothrombin time international 
normalized ratio, RR: respiratory rate, WBC: white blood cell count, BP: blood 
pressure. 
 
 21 
3.2 State Identification via K-mean Clustering 
Scatter plots with loess lines and the heatmap of means of medical vitals for states with 
different survival ranks are shown in Figure 3 and Figure 4, respectively. Based on the scatter plots 
and the heatmap, variables such as platelets and bicarbonate have higher values with higher ranks, 
while variables such as creatinine and BUN have lower values with higher ranks. The results show 
that the clustering has good performance that can clearly separate patients into different states 
based on their demographic information and medical conditions. 
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Figure 3 Means of medical conditions in different ranked states  
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Figure 4 Heatmap of medical vitals means 
3.3 Optimal Policy Identification via Q-learning 
The table with Q-values, Q-learning policy and clinician policy is shown in Table 6. The 
Q-values for choosing different treatments in different states were estimated. Higher Q-values 
represent higher overall expected reward, survival, after patients receive certain treatments in 
different states. The final Q-learning policy was conducted by choosing the treatment with the 
highest Q-value in each state. The probability of treatments from Q-learning policy in different 
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states was converted by the Q-values, while the probability of treatment from clinician policy was 
also calculated in the table.  
Table 6 Q-values, Q-learning policy, and clinician policy for different states1 
 
1 Q: Q-values; C: Probability derived from clinician policy. 
Rank 
NEPVO 
(Q) 
PVO 
(Q) 
NE 
(Q) 
None 
(Q) 
NEPVO 
(C) 
PVO 
(C) 
NE 
(C) 
None 
(C) 
Q-
learning 
Policy 
Clinician 
Policy 
1 2963.2 2949.0 3012.0 3004.3 0.64 0.08 0.03 0.25 NE NEPVO 
2 2978.9 3010.1 3096.0 2979.7 0.52 0.15 0.05 0.28 NE NEPVO 
3 3009.6 2997.0 3045.5 3010.7 0.51 0.12 0.07 0.30 NE NEPVO 
4 2988.1 3031.2 3000.9 3009.2 0.50 0.11 0.05 0.34 PVO NEPVO 
5 2992.2 2993.5 3006.8 2998.1 0.53 0.10 0.10 0.27 NE NEPVO 
6 3000.3 3018.1 3007.6 3020.6 0.51 0.20 0.04 0.25 None NEPVO 
7 2978.5 3030.3 3073.2 3020.1 0.45 0.14 0.02 0.39 NE NEPVO 
8 3006.0 3017.4 3017.4 2981.0 0.54 0.21 0.04 0.21 PVO NEPVO 
9 3006.4 3014.9 3042.6 3022.6 0.42 0.2 0.05 0.32 NE NEPVO 
10 3011.5 3013.7 3026.1 3025.7 0.46 0.15 0.04 0.35 NE NEPVO 
11 3005.2 3022.3 3019.6 3030.8 0.36 0.15 0.07 0.42 None None 
12 3004.3 3005.3 3001.4 3004.9 0.39 0.18 0.07 0.36 PVO NEPVO 
13 3002.9 3025.1 2988.8 3012.1 0.20 0.14 0.10 0.56 PVO None 
14 3012.7 3047.3 3017.3 3023.6 0.37 0.22 0.13 0.28 PVO NEPVO 
15 3023.7 3014.1 2977.7 3035.2 0.52 0.16 0.05 0.27 None NEPVO 
16 2999.7 3030.8 3004.4 3015.8 0.46 0.13 0.09 0.32 PVO NEPVO 
17 3010.1 3009.0 3035.9 3042.3 0.36 0.18 0.07 0.39 None None 
18 3003.0 3029.2 3004.4 3011.3 0.48 0.12 0.10 0.29 PVO NEPVO 
19 2997.9 3012.6 3054.0 3030.3 0.34 0.24 0.03 0.39 NE None 
20 2986.5 3025.7 3018.3 3029.7 0.34 0.16 0.10 0.40 None None 
21 2992.7 3039.9 3015.0 2993.2 0.38 0.15 0.08 0.40 PVO None 
22 3020.1 3023.1 3009.5 3015.5 0.34 0.16 0.10 0.40 PVO None 
23 3014.4 3007.5 3024.1 3013.4 0.40 0.20 0.03 0.38 NE NEPVO 
24 3017.5 3004.1 3006.2 3015.7 0.27 0.21 0.03 0.48 NEPVO None 
25 3013.2 3017.4 3029.7 3013.3 0.18 0.31 0.06 0.45 NE None 
26 3013.0 3028.2 3004.2 3017.7 0.35 0.23 0.05 0.37 PVO None 
27 3006.2 3034.0 3034.8 3022.8 0.42 0.18 0.04 0.36 NE NEPVO 
28 2998.2 3042.2 3024.8 3043.3 0.41 0.14 0.07 0.38 None NEPVO 
29 3034.4 3033.6 3017.7 3025.6 0.31 0.16 0.08 0.44 NEPVO None 
30 3007.9 3007.6 3042.0 3007.0 0.22 0.24 0.05 0.48 NE None 
31 3016.8 3047.4 2972.8 3034.3 0.28 0.12 0.07 0.54 PVO None 
32 2998.3 3051.6 3033.1 3053.3 0.27 0.16 0.04 0.52 None None 
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33 2996.0 3022.8 3016.2 3026.4 0.28 0.12 0.11 0.49 None None 
34 3008.9 3014.8 3007.9 3034.5 0.34 0.21 0.07 0.38 None None 
35 3014.9 3019.8 3029.9 3030.9 0.40 0.14 0.09 0.37 None NEPVO 
36 3019.6 3014.0 3021.8 3036.0 0.42 0.22 0.06 0.30 None NEPVO 
37 3011.4 3022.3 3022.6 3010.0 0.30 0.13 0.08 0.50 NE None 
38 3010.6 3022.2 3010.4 3016.5 0.24 0.23 0.11 0.42 PVO None 
39 3021.8 3036.5 3018.1 3033.5 0.20 0.17 0.09 0.54 PVO None 
40 3023.9 3039.8 3031.2 3048.6 0.20 0.26 0.07 0.47 None None 
41 3019.2 3019.5 3010.5 3021.2 0.28 0.22 0.06 0.44 None None 
42 3009.9 3008.2 3016.3 3033.6 0.33 0.17 0.09 0.41 None None 
43 3032.6 3027.5 3016.2 3036.5 0.31 0.28 0.07 0.33 None None 
44 3011.9 3027.4 3011.9 3031.9 0.29 0.19 0.09 0.43 None None 
45 3006.8 3009.7 3015.7 3016.6 0.30 0.22 0.06 0.41 None None 
46 3029.0 3033.1 3028.5 3064.0 0.25 0.23 0.04 0.48 None None 
47 3000.4 3033.1 3016.9 3018.5 0.24 0.18 0.12 0.46 PVO None 
48 3008.8 3031.1 3012.1 3035.1 0.27 0.21 0.08 0.43 None None 
49 3012.8 3011.9 3033.5 3047.0 0.27 0.15 0.08 0.50 None None 
50 3034.3 3025.1 3042.3 3035.1 0.17 0.22 0.09 0.51 NE None 
51 2985.5 3015.7 3038.7 3074.4 0.24 0.17 0.08 0.51 None None 
52 3018.7 3038.2 3026.8 3032.2 0.20 0.32 0.02 0.46 PVO None 
53 3034.9 3023.6 3051.5 3040.9 0.21 0.26 0.02 0.50 NE None 
54 3033.4 3042.4 2929.4 3048.7 0.18 0.34 0.01 0.46 None None 
55 3015.2 3012.0 3020.6 3015.9 0.25 0.25 0.08 0.42 NE None 
56 3027.6 3052.6 3056.1 3052.2 0.20 0.21 0.04 0.55 NE None 
57 3030.3 3034.0 3037.6 3038.1 0.21 0.21 0.05 0.52 None None 
58 3030.4 3031.7 3044.8 3064.4 0.21 0.25 0.07 0.47 None None 
59 3021.7 3038.1 3012.0 3055.0 0.24 0.20 0.07 0.50 None None 
60 3025.3 3035.1 3031.9 3035.8 0.20 0.15 0.09 0.55 None None 
61 3021.1 3040.6 3030.6 3033.7 0.20 0.19 0.02 0.58 PVO None 
62 3018.0 3049.7 2997.9 3041.5 0.42 0.19 0.02 0.37 PVO NEPVO 
63 3012.2 3005.3 3004.0 3022.1 0.22 0.17 0.06 0.55 None None 
64 3021.2 3029.1 3035.8 3059.9 0.19 0.15 0.04 0.62 None None 
65 3040.3 3040.5 3025.8 3068.3 0.17 0.13 0.04 0.67 None None 
66 3018.8 3040.7 3048.7 3038.9 0.22 0.19 0.08 0.51 NE None 
67 3013.6 3035.3 3056.5 3055.1 0.19 0.16 0.04 0.61 NE None 
68 2998.4 3045.6 3016.3 3036.8 0.20 0.14 0.10 0.56 PVO None 
69 3021.3 3062.5 3009.2 3050.3 0.24 0.18 0.04 0.55 PVO None 
70 3016.6 3060.1 3027.8 3067.0 0.21 0.16 0.02 0.61 None None 
71 3033.0 3037.1 3050.9 3065.5 0.18 0.16 0.08 0.58 None None 
72 3020.6 3016.3 3035.9 3038.2 0.15 0.19 0.08 0.59 None None 
73 3027.7 3053.7 3023.1 3060.2 0.14 0.25 0.02 0.60 None None 
74 3032.3 3054.8 3044.4 3040.3 0.25 0.17 0.08 0.50 PVO None 
75 3030.1 3065.6 3047.2 3062.5 0.11 0.24 0.04 0.61 PVO None 
Table 6 Continued 
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Boxplots of Q-learning policy at different states by clinicians’ first choices, the treatment 
with the highest probability selected by clinicians, are shown in Figure 5. In the clinicians’ first 
choice, there were only two treatments, NEPVO and None. When NEPVO is the clinicians’ first 
choice, there is significant difference between four treatments in Q-learning policy from the result 
of ANOVA (P-value = 0.000891). The post-hoc test result in Table 7 shows that NEPVO is 
significantly lower than the other three treatments, which means that NEPVO is the last choice 
suggested by the Q-learning policy. When no vasopressor (None) is the clinicians’ first choice, 
there are significant difference between four treatments in Q-learning policy from the result of 
ANOVA (P-value = 2e-16). The post-hoc test result shows that None is significantly higher than 
76 3021.6 3041.6 3031.4 3047.0 0.20 0.17 0.09 0.54 None None 
77 3020.3 3024.3 3031.3 3052.0 0.23 0.11 0.13 0.53 None None 
78 3014.3 3040.4 3026.1 3056.5 0.19 0.19 0.04 0.58 None None 
79 3047.1 3046.8 3040.8 3052.9 0.17 0.11 0.04 0.69 None None 
80 3038.5 3034.2 3058.3 3053.9 0.16 0.15 0.06 0.64 NE None 
81 3041.6 3056.8 3041.9 3086.6 0.14 0.18 0.03 0.65 None None 
82 3031.0 3034.7 3047.4 3038.8 0.12 0.17 0.05 0.65 NE None 
83 3017.4 3048.2 3040.1 3063.5 0.09 0.12 0.03 0.76 None None 
84 3024.3 3056.4 3062.9 3070.8 0.12 0.13 0.07 0.68 None None 
85 3038.5 3046.4 3059.0 3052.2 0.09 0.24 0.04 0.63 NE None 
86 3033.7 3038.3 3049.1 3064.9 0.13 0.07 0.07 0.74 None None 
87 3052.7 3050.0 3056.8 3060.0 0.09 0.16 0.05 0.70 None None 
88 3032.7 3034.9 3057.1 3063.9 0.17 0.25 0.07 0.51 None None 
89 3035.1 3056.0 3085.9 3090.6 0.11 0.2 0.01 0.68 None None 
90 3023.5 3045.5 3040.1 3030.7 0.12 0.17 0.11 0.60 PVO None 
91 3042.0 3050.8 3060.5 3056.8 0.10 0.20 0.05 0.66 NE None 
92 3059.1 3049.6 3061.8 3051.3 0.11 0.09 0.09 0.70 NE None 
93 3046.1 3062.4 3031.2 3057.0 0.17 0.17 0.05 0.61 PVO None 
94 3058.6 3066.3 3046.4 3046.9 0.06 0.13 0.03 0.78 PVO None 
95 3052.2 3070.0 3042.7 3087.9 0.13 0.11 0.04 0.72 None None 
96 3056.4 3052.7 3034.6 3095.2 0.07 0.10 0.02 0.81 None None 
97 3042.2 3051.2 3055.4 3072.6 0.12 0.14 0.05 0.68 None None 
98 3053.3 3063.2 3072.3 3052.5 0.19 0.16 0.07 0.59 NE None 
99 3060.5 3083.8 3092.4 3088.3 0.13 0.11 0.03 0.73 NE None 
100 3070.5 3078.4 3090.3 3088.5 0.14 0.18 0.04 0.64 NE None 
Table 6 Continued 
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the other three treatment, which means that the Q-learning policy suggests the same treatment, 
None, as clinicians. 
 
Figure 5 Multiple clinician treatment groups boxplot for Q-learning treatment 
 
Table 7 The ANOVA Post-Hoc test results of different treatments suggested by the Q-learning policy 
 
The heatmaps of treatments in different ranks based on clinician policy and Q-learning 
policy are shown in Figure 6 and Figure 7, respectively. From the figures below, we can see that 
the vasopressor treatments prescribed to patients with different conditions differs between the 
clinician policy and Q-learning policy. Most of the time, for patients with severe conditions (i.e., 
lower ranks), clinicians gave vasopressor treatments; however, the Q-learning policy tends to still 
prefer no treatments (None) to these severely ill patients. The heatmaps also show that clinicians 
 ANOVA post-hoc1 p-value 
(Clinician’s first choice: NEPVO) 
ANOVA post-hoc p-value 
(Clinician’s first choice: None) 
 NE NEPVO None NE NEPVO None 
NEPVO 0.0010* - - 5.7e-06* - - 
None 1 0.0324* - 5.0e-08* < 2e-16* - 
PVO 1 0.0085* 1 1  1.4e-07* 2.2e-06* 
1The post-hoc test was performed with Bonferroni correction. 
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tend to prescribe NEPVO to very severe patients, while the Q-learning policy only prescribed 
NEPVO to a few patients. When comparing NE and PVO, clinicians did not prescribe these 
treatments often, while the Q-learning policy prescribed NE and PVO more frequently to patients 
with severe conditions. 
 
Figure 6 Heatmap of treatments for ranks with clinician policy 
 
 
Figure 7 Heatmap of treatments for ranks with Q-learning policy 
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3.4 Policy Evaluation 
Results of off-policy evaluation of Q-learning policy, clinician policy and random policy 
with 18 bootstrapped datasets of the original, resampling with replacement, are summarized. The 
mean policy value of the Q-learning policy is 79.0 (SD = 12.2), while the mean policy value of the 
clinician policy and random policy are 60.1 (SD = 1.3) and 64.6 (SD = 5.9), respectively. The 
result of the one-way ANOVA shows that the p-value is less than 2e-16. We conclude that there 
is significant difference between the Q-learning policy, the clinician policy, and the random policy 
with 0.05 significance level. The post-hoc test shows that the value of the Q-learning policy is 
significantly higher than the clinician policy with p-value less than 2e-16, and significantly higher 
than the random policy with p-value 1.2-15, which means that patients can receive higher 
cumulative reward with Q-learning policy than with the clinician policy or the random policy. 
However, the p-value of the pairwise t-test between the clinician policy and the random policy is 
0.015, which is greater than 0.016 with the Bonferroni correction. So, we draw the conclusion that 
the policy value of random policy is significantly higher than clinician policy. 
 
Figure 8 Boxplot of policy values 
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4.0 Discussion 
Taking advantage of big electronic health record data and the development of modern 
machine learning technology, the clinicians can make fast, individualized, and interpretable 
treatment decisions through the use of reinforcement learning. The goal of this study was to apply 
reinforcement learning methods to develop an optimal vasopressor policy for sepsis patients based 
on observational data, and to better understand different rationales of treatment choices by 
clinicians and data-driven agents. Specifically, we developed a Q-learning method which aims to 
search for the optimal decisions targeting long-term survival, rather than focusing on acute 
resuscitation efforts. Our results showed that the policy based on the Q-learning has significantly 
higher policy value compared with the one obtained from the clinician policy or the random policy.  
We found that most clinicians prescribed vasopressors to patients in worse conditions, 
which correlates with our understanding that sicker patients are more likely to be treated with 
vasopressors. Prior research showed that low-dose (<0.04 U/min) vasopressors are safe and 
effective for the treatment of vasodilatory shock (Mutlu & Factor, 2004). Specifically, the 
clinicians tend to give combinations of first-line and second-line vasopressor treatments (NEPVO) 
to patients with worse conditions, which was consistent with the guidelines and prior research 
about first-line with other vasopressors being the vasopressor therapy in septic shock (Oba & Lone, 
2014). 
In contrast, the Q-learning policy tends to recommend different kinds of treatments than 
clinicians to patients with the worst conditions. The result indicates that the Q-learning policy 
tends to not provide vasopressor treatments, which was also observed in Pruinelli’s study where 
there was only 16% compliance to the guidelines of using vasopressors in patients with low mean 
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arterial pressure (MAP) (Pruinelli et al., 2016). There are many complications associated with 
administering vasopressors, such as tachycardia, atrial fibrillation, myocardial infarction, limb 
ischemia, and necrosis. Because of these serious complications, Q-learning policy may be more 
hesitant to start vasopressor therapy (Hollenberg, 2011), and be more exploratory and chooses 
other treatments than the ones typically chosen by clinicians. The Q-learning policy recommends 
using NE and PVO more frequently, which is consistent with the current research that recommends 
vasopressors should not be delayed until after fluid resuscitation and should be started to achieve 
a target MAP of ≥ 65 mmHg (Scheeren et al., 2019). Multiple vasopressors, NEPVO, was not 
suggested by the Q-learning policy as frequently for patients with good conditions. This could be 
due to the fact that these patients are in a generally good condition so that prescribing NEPVO 
may be seen as too extreme by the Q-learning policy because of the high risk for side-effects 
(Hollenberg, 2011). 
Our study found that the policy value is significantly lower for the clinicians’ choices than 
random policy, which is counterintuitive. Caution must be taken in the interpretations because that 
the two policies are largely different in many respects. We offer two factors that might contribute 
to this result: 1) potential confounding factors that were not included in our study are available for 
clinicians in their treatment decision making; and 2) clinician policy not only targeted in-hospital 
survival but also several intermediate outcomes, thus it may not necessarily be fair to compare on 
a single endpoint. The policy value of Q-learning policy is significantly higher than clinician policy 
showing that, retrospectively, if the patients received the treatments suggested from the Q-learning 
policy, their survival probability will increase compared to the existing clinician policy. The 
evaluation demonstrates that the vasopressor administration based on the Q-learning method 
values the long-term survival of the patients more than the clinician policy. 
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There are some limitations in this study. First, vasopressors are the treatments for 
hypotensive episodes in septic patients and provide relief for a short period of time, rather than 
treating the underlying causes of sepsis (Jeter, Josef, Shashikumar, & Nemati, 2019). Therefore, 
more treatments including antibiotic and fluids should be considered. Second, we used daily 
records of each patient as our analysis time step, which is not dense enough. In real life, medical 
decision making for septic shock patients in the ICU requires immediate diagnosis so that instant 
decisions can be made, which does not correspond to the long trajectory discretion. Moreover, 
patient’s vital status such as blood pressure, heart rate, and oxygen saturation can change 
dramatically within one day. With a finer time frame, estimation results will more closely resemble 
the real-time effect of the vasopressors. Third, the missing data in the datasets due to exclusion of 
patients with poor-quality data may compromise the representation of the datasets of the overall 
patient population. A more granular data is required to avoid a larger percentage of missing data 
at each time point. Fourth, the complexity of the disease and the variety of medical conditions for 
patients might require a larger study sample so more clusters can be formed. Fifth, the Q-value 
may be overestimated because the agent tends to choose the overestimated actions, which can be 
resolved by using double DQN (Deep Q-Network) or dueling DQN (Van Hasselt, Guez, & Silver, 
2016). Finally, the prioritized experience replay, the reweighting sampling improvement for the 
DQN algorithm training, can be applied to reduce the TD error of the batch data selected from the 
experience buffer (Schaul, Quan, Antonoglou, & Silver, 2015). 
In the future, our goal is to expand our method by incorporating short-term or immediate 
rewards based on the important intermediate outcomes. Ignoring these outcomes during the 
treatment decision process might worsen patient’s prognosis or reduce his/her quality of life 
(Yende et al., 2016). In addition, we may also consider more complicated methods that can balance 
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the long-term and short-term rewards with a quality of life study for patients after hospitalization 
to determine the influence of the choice of treatments on their post-discharge life. To improve the 
treatment decision making and form a more well-rounded treatment for each patient, we may also 
consider adding more treatments other than vasopressors (e.g., antibiotics and fluid use) in the 
future. We may also improve the model by replacing the discrete patient states with continuous 
patient states through the use of deep Q-learning (Haarnoja, Tang, Abbeel, & Levine, 2017) so 
that the monitoring can be on a patient’s unique conditions. Our future research will focus on those 
models that can map the latent structure of the balance of rewards, the complexity of treatments, 
and continuous trajectories. 
The use of artificial intelligence (AI) for guidance and outcome improvements has attracted 
great attention in the medical community. The purpose of using AI in clinical decision making is 
to provide support and suggestions, not to replace clinicians. Quality of health care also depends 
on some other unquantifiable factors, such as emotional intelligence (Norgeot, Glicksberg, & 
Butte, 2019), for patient outcomes can be affected not only by clinical decisions making but also 
the patient-doctor relationship. As for AI, we can enhance our modeling and apply machine 
reinforcement learning to diagnoses and treatments of other diseases in different clinical settings. 
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Appendix: R code 
The data analysis R code is presented in the GitHub repository: 
https://github.com/alryson52/Improving-treatment-decisions-for-sepsis-patients-by-
reinforcement-learning. 
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